Previous close | 8.20 |
Open | 7.90 |
Bid | 5.40 |
Ask | 7.20 |
Strike | 195.00 |
Expiry date | 2024-10-18 |
Day's range | 7.70 - 8.20 |
Contract range | N/A |
Volume | |
Open interest | 238 |
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.